Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Methadone, buprenorphine, and street drug interactions with antiretroviral medications.

Gruber VA, McCance-Katz EF.

Curr HIV/AIDS Rep. 2010 Aug;7(3):152-60. doi: 10.1007/s11904-010-0048-2. Review.

2.

Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.

McCance-Katz EF, Moody DE, Morse GD, Ma Q, DiFrancesco R, Friedland G, Pade P, Rainey PM.

Drug Alcohol Depend. 2007 Dec 1;91(2-3):269-78. Epub 2007 Jul 23.

3.

Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice.

Bruce RD, Altice FL, Gourevitch MN, Friedland GH.

J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):563-72. Review.

PMID:
16652030
4.

A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.

Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH.

Expert Rev Clin Pharmacol. 2013 May;6(3):249-69. doi: 10.1586/ecp.13.18. Review.

5.

Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir.

Bruce RD, Altice FL, Moody DE, Morse GD, Andrews L, Lin SN, Fang WB, Ma Q, Friedland GH.

J Acquir Immune Defic Syndr. 2010 Aug;54(5):511-4.

6.

Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.

McCance-Katz EF, Sullivan LE, Nallani S.

Am J Addict. 2010 Jan-Feb;19(1):4-16. doi: 10.1111/j.1521-0391.2009.00005.x. Review.

7.

Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients.

Baker JR, Best AM, Pade PA, McCance-Katz EF.

Ann Pharmacother. 2006 Mar;40(3):392-6. Epub 2006 Feb 28.

PMID:
16507617
8.

The impact of recent cocaine use on plasma levels of methadone and buprenorphine in patients with and without HIV-infection.

Tetrault JM, McCance-Katz EF, Moody DE, Fiellin DA, Lruie BS, DInh AT, Fiellin LE.

J Subst Abuse Treat. 2015 Apr;51:70-4. doi: 10.1016/j.jsat.2014.10.010. Epub 2014 Nov 5.

PMID:
25480096
9.

Drug interactions associated with methadone, buprenorphine, cocaine, and HIV medications: implications for pregnant women.

McCance-Katz EF.

Life Sci. 2011 May 23;88(21-22):953-8. doi: 10.1016/j.lfs.2010.09.016. Epub 2010 Oct 19. Review.

10.
11.

Interactions between recreational drugs and antiretroviral agents.

Antoniou T, Tseng AL.

Ann Pharmacother. 2002 Oct;36(10):1598-613. Review.

PMID:
12243611
12.

Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone.

Sekar V, Tomaka F, Lefebvre E, De Pauw M, Vangeneugden T, van den Brink W, Hoetelmans R.

J Clin Pharmacol. 2011 Feb;51(2):271-8. doi: 10.1177/0091270010365558. Epub 2010 Apr 26. No abstract available.

PMID:
20421512
14.

Pharmacokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence.

Maas B, Kerr T, Fairbairn N, Montaner J, Wood E.

Expert Opin Drug Metab Toxicol. 2006 Aug;2(4):533-43. Review.

PMID:
16859402
15.
16.

Decreased methadone effect after ritonavir initiation.

Geletko SM, Erickson AD.

Pharmacotherapy. 2000 Jan;20(1):93-4.

PMID:
10641980
17.

Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir.

Clarke S, Mulcahy F, Bergin C, Reynolds H, Boyle N, Barry M, Back DJ.

Clin Infect Dis. 2002 Apr 15;34(8):1143-5. Epub 2002 Mar 19.

PMID:
11915005
18.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
19.

Association between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment.

Tetrault JM, Kozal MJ, Chiarella J, Sullivan LE, Dinh AT, Fiellin DA.

J Addict Med. 2013 Mar-Apr;7(2):102-7. doi: 10.1097/ADM.0b013e31827f9bdf.

20.

Self-reported side effects in buprenorphine and methadone patients receiving antiretroviral therapy: results from the MANIF 2000 cohort study.

Carrieri MP, Roux P, Cohen J, Ravaux I, Dellamonica P, Protopopescu C, Spire B, Rosenblum A.

Addiction. 2010 Dec;105(12):2160-8. doi: 10.1111/j.1360-0443.2010.03108.x. Epub 2010 Sep 15.

PMID:
20840169

Supplemental Content

Support Center